Carisma Therapeutics
CARM
CARM was delisted on the 10th of October, 2025.
33 hedge funds and large institutions have $843K invested in Carisma Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 6 closing their positions.
2.17% less ownership
Funds ownership: 9.53% → 7.36% (-2.2%)
8% less funds holding
Funds holding: 36 → 33 (-3)
46% less capital invested
Capital invested by funds: $1.56M → $843K (-$714K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$7.55K |
| 2 |
Citigroup
New York
|
+$3.73K |
| 3 |
Goldman Sachs
New York
|
+$1.12K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$21 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$281K |
| 2 |
Jane Street
New York
|
-$59.1K |
| 3 |
Renaissance Technologies
New York
|
-$11.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.98K |
| 5 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$4.45K |
CARM Hedge Fund Activity: Q3 2025 in Review
33 of the 7,622 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2025, worth a combined $843K — down 46% from $1.56M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CARM and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Virtu Financial, opening a new position worth an estimated $7.55K. The largest seller was AJU IB Investment Company, exiting entirely with an estimated $281K sold.
- 33 institutional investors held Carisma Therapeutics (CARM) as of Q3 2025, down from 36 in Q2 2025.
- Funds reported $843K of Carisma Therapeutics stock for Q3 2025, down 46% quarter-over-quarter.
- 3 funds opened new Carisma Therapeutics positions in Q3 2025 and 6 closed out, a net change of -3 holders.
- The largest Carisma Therapeutics buyer in Q3 2025 was Virtu Financial, an estimated $7.55K added.
- The largest Carisma Therapeutics seller in Q3 2025 was AJU IB Investment Company, an estimated $281K sold.
Based on aggregated 13F filings for Q3 2025.